Introduction
============

In patients with diffuse large B cell lymphoma (DLBCL), rituximab-based chemotherapy regimens can achieve superior long-term progression-free survival (PFS) and overall survival (OS) rates relative to regimens that do not contain rituximab ([@b1-mco-0-0-1930]). However, even in the rituximab era, approximately 10--15% of patients with DLBCL treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) fail to achieve complete remission (CR) ([@b2-mco-0-0-1930],[@b3-mco-0-0-1930]). Such patients can often be treated with salvage chemotherapy regimens and subsequent autogenous stem cell transplantation (ASCT) ([@b4-mco-0-0-1930],[@b5-mco-0-0-1930]). To date, there has been no definite consensus on salvage therapy in this patient population and little information on the ideal treatment regimen, with data from randomized trials of salvage therapy failing to reveal significant differences between regimens ([@b5-mco-0-0-1930]). Two randomized clinical studies have compared treatment regimens prior to ASCT. In the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) study, R-ICE (rituximab, ifosfamide, carboplatin, etoposide) was compared with R-DHAP (rituximab, cytosine arabinoside, cisplatin, dexamethasone), followed by ASCT with or without rituximab maintenance, and no difference was identified between the regimens ([@b4-mco-0-0-1930]). In the LY02 study, R-DHAP was compared with R-GDP (rituximab, gemcitabine, dexamethasone, cisplatin) before ASCT. Although no difference in OS was reported, R-GDP was associated with fewer AEs, improved quality of life (QOL), and less-frequent hospitalization ([@b5-mco-0-0-1930]). In a recent patient-level analysis of outcomes of refractory DLBCL from two large randomized trials and two academic databases (SCHOLAR-1) ([@b6-mco-0-0-1930]), an objective response rate of 26% (CR 7%) to the next line of therapy was demonstrated, with a median OS of 6.3 months. This analysis also showed that a poor outcome was associated with relapsed and refractory DLBCL. The results from these previous studies indicate a clear need for novel therapies to improve outcomes in this patient population.

We therefore sought to determine the safest and most effective regimen in the clinical setting. Furthermore, with current treatment trends, we determined which regimens are changing from administration in an inpatient to an outpatient setting.

Patients and methods
====================

### Patients

This retrospective analysis was conducted at Kansai Medical University Hospital and Kansai Medical University Medical Center. Among 530 patients diagnosed with DLBCL from April 2002 to November 2017, 131 relapsed and refractory patients who received salvage therapy were enrolled in this study. Primary treatment included R-CHOP or R-CHOP-like regimens. Tumor responses were assessed according to the classification of the International Workshop to Standardize Response Criteria for Non-Hodgkin\'s Lymphoma 1999. Relapse was defined as emerging new sites or enlarging sites and refractory disease was defined as progressive/stable disease during first-line treatment. Performance status was evaluated by an Eastern Cooperative Oncology Group (ECOG) performance status score. To predict prognosis, we used both the international prognostic index (IPI) and the National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI). Although IPI was the most powerful prognostic scale before the advent of rituximab, its power has reduced ([@b7-mco-0-0-1930]). NCCN-IPI has been reported more accurate than older IPI in rituximab era ([@b8-mco-0-0-1930]). However, NCCN-IPI has not been evaluated enough in Japan, thus, we used both scales.

### Statistical analysis

Progression-free survival 2 (PFS2) was defined as the period from the start of initial treatment to the second exacerbation or death after second-line treatment. OS was calculated as the time from diagnosis until the time of death or the last clinical follow-up.

Survival curves were generated using the Kaplan-Meier method, and differences were evaluated using the log-rank test. Multivariate Cox-proportional hazards models were used to determine whether baseline characteristics were associated with PFS2 and OS. All statistical tests were two-sided, statistical significance was defined as P\<0.05, and 95% confidence intervals (CIs) were calculated. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R version 2.13.0 (The R Foundation). Specifically, EZR is a modified version of R Commander (version 1.6--3) that adds statistical functions frequently used in biostatistics ([@b9-mco-0-0-1930]). Toxicity was evaluated according to the Common Terminology Criteria for Adverse Events (AEs) (CTCAE 4.0, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health, National Cancer Institute, \[<http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40>\]). This study was conducted in accordance with the ethical principles of the Declaration of Helsinki, and was approved by the institutional review board of Kansai Medical University.

Results
=======

### Patient characteristics

Clinical characteristics of the 131 enrolled patients (median age, 68 years; age range, 35--87 years; 54% male) are shown in [Table I](#tI-mco-0-0-1930){ref-type="table"}. PS over 2 was 7%. Stage I was 11%, Stage II was 16%, Stage III was 18%, and Stage IV was 55%. Using the IPI, 22% of patients were classified as being at low risk, 18% as low-intermediate (LI) risk, 22% as high-intermediate (HI) risk, and 38% as high risk. In comparison, under the National Comprehensive Cancer Network (NCCN)-IPI, 7% of patients were classified as being at low risk, 40% as LI, 50% as HI, and 3% as high risk. The median follow-up period was 33.6 months (range, 1.9--155.9 months).

### Salvage regimens

The most common salvage regimen was R-DeVIC (rituximab, etoposide, dexamethasone, ifosfamide, carboplatin) (42%), followed by R-ESHAP (rituximab, etoposide, solumedrol, cytarabine, cisplatin) (23%) ([Fig. 1](#f1-mco-0-0-1930){ref-type="fig"}). Other aggressive regimens were administered to 12% of patients, and included R-CHASE (rituximab, cyclophosphamide, cytosine arabinoside, etoposide, dexamethasone) (n=5), rituximab plus methotrexate-based treatment (n=5), R-CHOP-based treatment (n=3), R-GDP (rituximab, gemcitabine, cisplatin, dexamethasone) (n=2), and R-EPOCH (rituximab, etoposide, vincristine, doxorubicin, cyclophosphamide, prednisolone) (n=1). Finally, 23% of patients underwent palliative therapy such as radiation, rituximab monotherapy, oral etoposide, or oral prednisolone.

### Survival

Median OS by regimen was 45.7 (30.7--75.8) months for R-DeVIC, 41.8 (23.4--92.3) months for palliative therapy, 29.4 (14.1--98.1) months for R-ESHAP, and 28.5 (13.5-not applicable) months for aggressive regimens (P=0.937; [Fig. 2](#f2-mco-0-0-1930){ref-type="fig"}).

### Outcome of salvage ASCT

Twenty-five patients underwent ASCT, and had PFS2 of 39.0 (19.2--56.6) months compared with 22.3 (15.2--29.0) months in patients who did not undergo ASCT (P=0.077; [Fig. 3A](#f3-mco-0-0-1930){ref-type="fig"}). OS was 75.6 (51.8-not applicable) months in patients undergoing ASCT vs. 33.5 (25.6--45.6) months in patients who did not undergo ASCT (P=0.033; [Fig. 3B](#f3-mco-0-0-1930){ref-type="fig"}).

### Prognostic factors

Multivariate analysis was performed to identify risk factors associated with PFS2 and OS. Age over 70 years, male sex, PS\>3, more than HI in IPI, and more than HI in NCCN-IPI were evaluated. NCCN-IPI \[Hazard ratio (HR)\]: 2.22, 95% CI: 1.46--3.38, P=0.0001), male (HR: 1.60, 95% CI: 1.06--2.41, P=0.024), and PS\>3 (HR: 1.47, 95% CI: 1.06--2.03, P=0.022) remained as significant factors affecting PFS2 in multivariate analysis, whereas other factors were eliminated by backward stepwise selection. NCCN-IPI (HR: 2.56, 95% CI: 1.56--4.20, P=0.0002), IPI (HR: 1.68, 95% CI: 1.00--2.82, P=0.049), and male (HR: 1.58, 95% CI: 1.00--2.47, P=0.049) remained as significant factors affecting survival.

### Regimen transmission to outpatient chemotherapy

Our facilities established an outpatient chemotherapy unit in 2014, after which patients were primarily treated as outpatients. We analyzed the change in proportion of regimen prior to and after 2014 ([Fig. 4](#f4-mco-0-0-1930){ref-type="fig"}). Before 2014, R-DeVIC was the most commonly administered regimen (37%), followed by R-ESHAP (31%). After 2014, R-DeVIC use increased to 46%, whereas R-ESHAP decreased to 17%.

### Comparison between R-DeVIC and R-ESHAP

In our facilities, more than half of enrolled patients were treated with either R-DeVIC or R-ESHAP as salvage therapy. Thus, we compared the efficacy of these two regimens. The treatment schedule is shown in [Table II](#tII-mco-0-0-1930){ref-type="table"}, and patient characteristics are presented in [Table III](#tIII-mco-0-0-1930){ref-type="table"}. In total, 55 patients were treated with R-DeVIC and 30 patients were treated with R-ESHAP. Median age was 70 years in the R-DeVIC group and 61 years in the R-ESHAP group. The most frequent adverse events other than hematological events (grade≥3) were febrile neutropenia (n=4 in R-DeVIC, n=8 in R-ESHAP) followed by infection (n=1 in R-DeVIC, n=3 in R-ESHAP). Early-relapse patients comprised 44% of the R-DeVIC group and 77% of the R-ESHAP group. PFS2 was 24.7 (15.5--39.0) months in the R-DeVIC group and 13.8 (10.2--27.4) months in the R-ESHAP group (P=0.643; [Fig. 5A](#f5-mco-0-0-1930){ref-type="fig"}), while OS was 45.7 (30.7--75.8) months in the R-DeVIC group and 29.4 (14.1--98.1) months in the R-ESHAP group (P=0.53; [Fig. 5B](#f5-mco-0-0-1930){ref-type="fig"}).

Discussion
==========

In the present analysis, R-DeVIC and R-ESHAP were used more frequently than other salvage regimens. Given that the choice of regimen was at the physician\'s discretion, it is difficult to determine the precise reason for selecting a particular regimen. However, we suggest that several factors may have contributed to regimen choice. First, R-ESHAP was administered to patients with more aggressive disease progression and worse condition, but with younger age. Physicians may have selected this regimen with the intention of subsequent salvage ASCT, as 42% of patients who received R-ESHAP later underwent ASCT. However, R-ESHAP treatment was associated with more AEs compared with R-DeVIC treatment. After 2014, the number of patients receiving R-ESHAP decreased with the establishment of our outpatient facility.

R-DeVIC was most commonly used regimen throughout the present study. The decisive factor in the selection of R-DeVIC vs. R-ESHAP is the need for hospitalization ([Table II](#tII-mco-0-0-1930){ref-type="table"}). As R-ESHAP is administered via a central venous catheter, patients require hospitalization. However, R-DeVIC can be given via a peripheral vein, and this type of regimen became more common after the establishment of the outpatient chemotherapy unit in 2014. Given that previous large trials have shown no difference between the salvage regimens, we suggest that the use of the outpatient unit is the likely reason for the increase in R-DeVIC use observed in our analysis.

Unfortunately, our findings failed to show a difference between R-DeVIC and R-ESHAP with respect to PFS2 and OS. However, patients that received R-DeVIC tended to have a better prognosis. As detailed above, R-ESHAP was selected in patients with more aggressive disease progression and worse condition. Thus, R-ESHAP may have been associated with a tendency toward worse prognosis.

ASCT has been previously shown to be an effective salvage therapy in patients with DLBCL ([@b4-mco-0-0-1930],[@b5-mco-0-0-1930]). In the present study, the number of patients who received ASCT was low compared with the patient population in SCHOLAR-1 study ([@b6-mco-0-0-1930]). This difference may be attributable to a higher median age in the present analysis (55 years vs. 68 years).

In multivariate analysis, NCCN-IPI was a significant predictive factor both in PFS2 and OS. NCCN-IPI has not been evaluated in second line treatment. NCCN-IPI might become a promising predictive scale for DLBCL.

The present study had some limitations, including its retrospective design, use of only two study sites, and small sample size. Furthermore, no genetic analysis using techniques such as fluorescence in situ hybridization (FISH) and immunostaining was performed. Genetic analysis is carried out in clinical settings, and its relevance to prognosis has been established. However, FISH is not covered by insurance in Japan, and there are disparities in immunostaining results between facilities. Thus, these evaluations are not necessarily performed routinely in clinical practice in Japan. We could not analyze QOL of patients although it is the important point to evaluate. The analyze of QOL should be conducted prospectively.

In conclusion, we were unable to identify the optimal salvage regimen for patients with DLBCL in the present study. However, we identified the effect of establishing an out-patient chemotherapy unit on salvage therapy selection, and anticipate that regimens administered via peripheral vein will become predominant in the future.
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![Percentages of salvage therapies. The aggressive regimen was applied in 12% of cases, and included R-CHASE (n=5), rituximab plus methotrexate-based (n=5), R-CHOP like (n=3), R-GDP (n=2) and R-EPOCH (n=1). Palliative therapy included radiation only, rituximab monotherapy, oral etoposide and oral prednisolone. R-CHASE, rituximab, cyclophosphamide, cytosine arabinoside, etoposide, dexamethasone; R-GDP, rituximab, gemcitabine, cisplatin, dexamethasone; R-EPOCH, rituximab, etoposide, vincristine, doxorubicin, cyclophosphamide, prednisolone; R-DeVIC, rituximab, etoposide, dexamethasone, ifosfamide, carboplatin; R-ESHAP, rituximab, etoposide, solumedrol, cytarabine, cisplatin.](mco-11-06-0557-g00){#f1-mco-0-0-1930}
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![PFS and OS of patients with ASCT. (A) PFS of patients with ASCT. (B) OS of patients with ASCT. A total of 25 patients received ASCT. PFS, progression-free survival; OS, overall survival; ASCT, autologous stem cell transplantation.](mco-11-06-0557-g02){#f3-mco-0-0-1930}

![Transition of regimen in the outpatient chemotherapy unit. An outpatient chemotherapy unit was established in 2014. Prior to 2014, R-DeVIC was the most common regimen, followed by R-ESHAP. After 2014, R-DeVIC increased to 46%, whereas R-ESHAP decreased to 17%. R-DeVIC, rituximab, etoposide, dexamethasone, ifosfamide, carboplatin; R-ESHAP, rituximab, etoposide, solumedrol, cytarabine, cisplatin.](mco-11-06-0557-g03){#f4-mco-0-0-1930}

![Comparison of PFS and OS between R-DeVIC and R-ESHAP. (A) Comparison of PFS between R-DeVIC and R-ESHAP. (B) Comparison of OS between R-DeVIC and R-ESHAP. PFS, progression-free survival; OS, overall survival; R-DeVIC, rituximab, etoposide, dexamethasone, ifosfamide, carboplatin; R-ESHAP, rituximab, etoposide, solumedrol, cytarabine, cisplatin.](mco-11-06-0557-g04){#f5-mco-0-0-1930}

###### 

Patient characteristics.

  Characteristics             Number (%)
  --------------------------- -------------
  Number of patients          131
  Median age, years (range)   68 (35--87)
  Male                        71 (54)
  PS ≥2                       9 (7)
  Stage                       
    I                         14 (11)
    II                        21 (16)
    III                       24 (18)
    IV                        72 (55)
  IPI                         
    Low                       29 (22)
    Low-int                   23 (18)
    High-int                  29 (22)
    High                      50 (38)
  NCCN-IPI                    
    Low                       10 (7)
    Low-int                   52 (40)
    High-int                  65 (50)
    High                      4 (3)

PS, performance status; int, intermediate; IPI, International Prognosis Index; NCCN-IPI, The National Comprehensive Cancer Network- International Prognosis Index.

###### 

Treatment schedule.

                  R-DeVIC (peripheral vein)   R-ESHAP (central vein)                                                                
  --------------- --------------------------- ------------------------ --- --- -------------------- --------------- --- --- --- --- ---
  Rituximab       375 mg/m^2^                 x                                Rituximab            375 mg/m^2^     x               
  Ifosfamide      15,00 mg/m^2^               x                        x   x   Cytarabine           2,000 mg/m^2^   x   x   x   x   
  Carboplatin     300 mg/m^2^                 x                                Cisplatin            25 mg/m^2^      x   x   x   x   x
  Etoposide       100 mg/m^2^                 x                        x   x   Etoposide            40 mg/m^2^      x               
  Dexamethasone   33 mg                       x                        x   x   Methylprednisolone   500 mg          x   x   x   x   

R-DeVIC, rituximab, etoposide, dexamethasone, ifosfamide, carboplatin; R-ESHAP, rituximab, etoposide, solumedrol, cytarabine, cisplatin.

###### 

Comparison between R-DeVIC and R-ESHAP.

  Characteristics             R-DeVIC       R-ESHAP
  --------------------------- ------------- -------------
  Patients, n                 55            30
  Median age, years (range)   70 (35--84)   61 (41--68)
  Male sex, %                 58            52
  PS ≥2 at relapse, n (%)     2 (4)         6 (19)
  Stage at Dx, n (%)                        
    I                         6 (11)        1 (3)
    II                        8 (15)        4 (13)
    III                       13 (24)       7 (23)
    IV                        28 (50)       19 (61)
  Stage at relapse, n (%)                   
    I                         2 (5)         5 (16)
    II                        11 (20)       1 (3)
    III                       18 (33)       9 (29)
    IV                        24 (42)       16 (52)
  AE, n                                     
    FN                        4             8
    Infection                 1             3
    Ileus                     1             1
  DIC                         0             1
    Heart disease             0             1
  Early relapse, %            44            77
  ASCT, %                     16            42

R-DeVIC, rituximab, etoposide, dexamethasone, ifosfamide, carboplatin; R-ESHAP, rituximab, etoposide, solumedrol, cytarabine, cisplatin; Dx, diagnosis; AE, adverse event; FN, febrile neutropenia; DIC, disseminated intravascular coagulation; ASCT, autologous stem cell transplantation.
